Boehringer Ingelheim to present Pradaxa data at ESC 2014

Boehringer Ingelheim has announced that it will be sharing new data on its oral anticoagulant Pradaxa at the upcoming European Society of Cardiology (ESC) 2014 congress.

The conference, which runs from August 30th to September 3rd 2014 in Barcelona, will give the company an opportunity to provide further clinical insights on Pradaxa that will help to inform future anticoagulation treatment decisions.

Data from the first 10,000 patients included in the GLORIA-AF Registry Programme will be shared, offering new insights into patterns of antithrombotic treatment use for stroke prevention among atrial fibrillation patients.

Following this, a RE-LY sub-analysis will be presented comparing the effects of warfarin and Pradaxa on kidney function in atrial fibrillation patients requiring anticoagulation.

Additionally, further new data sets from company-sponsored studies involving Pradaxa in atrial fibrillation, deep vein thrombosis and pulmonary embolism will also feature as poster and oral presentations.

This comes after the firm last week commenced a study evaluating Pradaxa as a treatment for non-valvular atrial fibrillation patients who have undergone surgery.